Cellectis (CLLS) Competitors $1.64 +0.05 (+3.14%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CLLS vs. CYRX, ALVO, NGNE, BTMD, VYGR, DSGN, CTNM, TNGX, SLRN, and CGCShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Cryoport (CYRX), Alvotech (ALVO), Neurogene (NGNE), biote (BTMD), Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), Contineum Therapeutics (CTNM), Tango Therapeutics (TNGX), Acelyrin (SLRN), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Cryoport Alvotech Neurogene biote Voyager Therapeutics Design Therapeutics Contineum Therapeutics Tango Therapeutics Acelyrin Canopy Growth Cryoport (NASDAQ:CYRX) and Cellectis (NASDAQ:CLLS) are both small-cap transportation companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability. Does the MarketBeat Community believe in CYRX or CLLS? Cellectis received 165 more outperform votes than Cryoport when rated by MarketBeat users. Likewise, 65.33% of users gave Cellectis an outperform vote while only 65.05% of users gave Cryoport an outperform vote. CompanyUnderperformOutperformCryoportOutperform Votes24265.05% Underperform Votes13034.95% CellectisOutperform Votes40765.33% Underperform Votes21634.67% Do analysts prefer CYRX or CLLS? Cryoport presently has a consensus price target of $12.29, indicating a potential upside of 56.31%. Cellectis has a consensus price target of $7.00, indicating a potential upside of 326.83%. Given Cellectis' stronger consensus rating and higher probable upside, analysts clearly believe Cellectis is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cryoport 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Cellectis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, CYRX or CLLS? Cryoport has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.09, indicating that its stock price is 209% more volatile than the S&P 500. Do institutionals & insiders have more ownership in CYRX or CLLS? 92.9% of Cryoport shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 10.1% of Cryoport shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is CYRX or CLLS more profitable? Cryoport has a net margin of -70.08% compared to Cellectis' net margin of -234.39%. Cryoport's return on equity of -13.35% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets Cryoport-70.08% -13.35% -6.43% Cellectis -234.39%-74.55%-22.65% Which has stronger valuation and earnings, CYRX or CLLS? Cryoport has higher revenue and earnings than Cellectis. Cryoport is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoport$226.11M1.72-$99.59M-$3.38-2.33Cellectis$29.07M3.14-$101.06M-$1.30-1.26 Does the media favor CYRX or CLLS? In the previous week, Cryoport had 1 more articles in the media than Cellectis. MarketBeat recorded 3 mentions for Cryoport and 2 mentions for Cellectis. Cryoport's average media sentiment score of 0.97 beat Cellectis' score of 0.95 indicating that Cryoport is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cryoport 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCryoport and Cellectis tied by winning 9 of the 18 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.16M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-1.2646.7389.8217.18Price / Sales3.14415.011,116.21116.95Price / CashN/A182.1042.8937.86Price / Book1.083.894.784.78Net Income-$101.06M-$42.21M$120.23M$225.60M7 Day Performance-6.82%-2.15%-1.92%-1.23%1 Month Performance-12.30%4.20%11.49%3.36%1 Year Performance-51.34%18.39%30.57%16.60% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis3.1721 of 5 stars$1.64+3.1%$7.00+326.8%-53.8%$91.16M$29.07M-1.26290CYRXCryoport3.0208 of 5 stars$7.78+1.2%$12.50+60.7%-49.8%$384.57M$226.11M-2.321,170Analyst ForecastGap DownALVOAlvotech2.6628 of 5 stars$12.07+2.3%$18.00+49.1%+8.7%$377.19M$391.87M-6.381,026NGNENeurogene3.7408 of 5 stars$24.49+4.2%$60.83+148.4%N/A$363.80M$925,000.000.0090BTMDbiote3.0893 of 5 stars$6.60+3.6%$9.11+38.0%+20.8%$358.62M$193.06M24.77194Positive NewsGap UpVYGRVoyager Therapeutics4.6114 of 5 stars$6.49+3.5%$17.00+161.9%-27.6%$354.55M$250.01M8.83100DSGNDesign Therapeutics0.9221 of 5 stars$6.24+11.4%$7.00+12.2%+143.2%$353.32MN/A-7.1840News CoveragePositive NewsCTNMContineum Therapeutics1.9558 of 5 stars$13.69-2.4%$29.25+113.7%N/A$352.93M$50M0.0031News CoverageTNGXTango Therapeutics1.8563 of 5 stars$3.19+4.2%$13.14+312.0%-68.5%$342.66M$43.38M-2.5990News CoverageSLRNAcelyrin2.7884 of 5 stars$3.40+5.3%$11.75+245.6%-55.8%$341.12MN/A-1.31135CGCCanopy Growth2.4368 of 5 stars$3.10-0.3%$3.50+12.9%-41.0%$337.71M$220.27M-0.631,029Analyst RevisionNews Coverage Related Companies and Tools Related Companies CYRX Alternatives ALVO Alternatives NGNE Alternatives BTMD Alternatives VYGR Alternatives DSGN Alternatives CTNM Alternatives TNGX Alternatives SLRN Alternatives CGC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLLS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
